非肌层浸润性膀胱肿瘤的临床研究进展
Clinical Research Progress of Non-Muscular Invasive Bladder Cancer
摘要: 膀胱癌是泌尿系统常见的恶性肿瘤。根据肿瘤浸润深度可分为非肌肉浸润性膀胱癌(Non-Muscular Invasive Bladder Cancer, NMIBC)和肌肉浸润性膀胱癌(Muscular Invasive Bladder Cancer, MIBC)。大约50%~70%的NMIBC患者会在5年内复发。另外，10%~15%的NMIBC患者将发展为MIBC。本文就NMIBC的病因、手术及术后辅助化疗进行综述。
Abstract: Bladder cancer is a common malignant tumor in the urinary system. According to the depth of tu-mor invasion, it can be divided into non-muscle invasive bladder cancer (NMIBC) and muscle inva-sive bladder cancer (MIBC). About 50%~70% of NMIBC patients will relapse within 5 years. In ad-dition, 10%~15% of NMIBC patients will develop MIBC. This article reviews the etiology, surgery and postoperative adjuvant chemotherapy of NMIBC.
文章引用：李壮, 任海林. 非肌层浸润性膀胱肿瘤的临床研究进展[J]. 临床医学进展, 2022, 12(9): 8096-8101. https://doi.org/10.12677/ACM.2022.1291166

参考文献

[1] Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 7-30. [Google Scholar] [CrossRef] [PubMed]
[2] Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. [Google Scholar] [CrossRef] [PubMed]
[3] 韩苏军, 张思维, 陈万青, 李长岭. 中国膀胱癌发病现状及流行趋势分析[J]. 癌症进展, 2013, 11(1): 89-95.
[4] Shariat, S.F., Sfakianos, J.P., Droller, M.J., et al. (2010) The Effect of Age and Gender on Bladder Cancer: A Critical Review of the Literature. BJU International, 105, 300-308. [Google Scholar] [CrossRef] 
[5] Shariat, S.F., Milowsky, M. and Droller, M.J. (2009) Bladder Cancer in the Elderly. Urologic Oncology, 27, 653-667. [Google Scholar] [CrossRef] [PubMed]
[6] Dobruch, J., Daneshmand, S., Fisch, M., et al. (2016) Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. European Urology, 69, 300-310. [Google Scholar] [CrossRef] [PubMed]
[7] Hurst, C.D., Alder, O., Platt, F.M., et al. (2017) Genomic Sub-types of Non-Invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency. Cancer Cell, 32, 701-715.e7. [Google Scholar] [CrossRef] [PubMed]
[8] Freedman, N.D., Silverman, D.T., Hollenbeck, A.R., Schatzkin, A. and Abnet, C.C. (2011) Association between Smoking and Risk of Bladder Cancer among Men and Women. JAMA, 306, 737-745. [Google Scholar] [CrossRef] [PubMed]
[9] van Osch, F.H., Jochems, S.H., van Schooten, F.J., Bryan, R.T. and Zeegers, M.P. (2016) Quantified Relations between Exposure to Tobacco Smoking and Bladder Cancer Risk: A Me-ta-Analysis of 89 Observational Studies. International Journal of Epidemiology, 45, 857-870. [Google Scholar] [CrossRef] [PubMed]
[10] Coussens, L.M. and Werb, Z. (2002) Inflammation and Cancer. Nature, 420, 860-867. [Google Scholar] [CrossRef] [PubMed]
[11] Moschini, M., Zaffuto, E., Karakiewicz, P.I., et al. (2019) External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer. European Urology, 75, 319-328. [Google Scholar] [CrossRef] [PubMed]
[12] Burger, M., Catto, J.W., Dalbagni, G., Grossman, H.B., Herr, H., Karakiewicz, P., Kassouf, W., Kiemeney, L.A., La Vecchia, C., Shariat, S. and Lotan, Y. (2013) Epidemiology and Risk Factors of Urothelial Bladder Cancer. European Urology, 63, 234-241. [Google Scholar] [CrossRef] [PubMed]
[13] Cumberbatch, M.G.K., Jubber, I., Black, P.C., et al. (2018) Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. Eu-ropean Urology, 74, 784-795. [Google Scholar] [CrossRef] [PubMed]
[14] Marcos-Gragera, R., Mallone, S., Kiemeney, L.A., et al. (2015) Urinary Tract Cancer Survival in Europe 1999-2007: Results of the Population-Based Study EUROCARE-5. European Journal of Cancer, 51, 2217-2230. [Google Scholar] [CrossRef] [PubMed]
[15] Babjuk, M., Böhle, A., Burger, M., et al. (2017) EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder: Update 2016. European Urology, 71, 447-461. [Google Scholar] [CrossRef] [PubMed]
[16] Xiong, Y., Li, J., Ma, S., et al. (2017) A Meta-Analysis of Nar-row Band Imaging for the Diagnosis and Therapeutic Outcome of Non-Muscle Invasive Bladder Cancer. PLOS ONE, 12, e0170819. [Google Scholar] [CrossRef] [PubMed]
[17] Burger, M., Grossman, H.B., Droller, M., et al. (2013) Photo-dynamic Diagnosis of Non-Muscle-Invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-Analysis of Detection and Recurrence Based on Raw Data. European Urology, 64, 846-854. [Google Scholar] [CrossRef] [PubMed]
[18] Zhou, A.G., Liu, Y., Cyr, M.S., et al. (2016) Role of Tetrasomy for the Diagnosis of Urothelial Carcinoma Using UroVysion Fluorescent in Situ Hybridization. Archives of Pathology & Laboratory Medicine, 140, 552-559. [Google Scholar] [CrossRef] 
[19] Karim, C., et al. (2015) Quality of Diagnostic Staging in Patients with Bladder Cancer: A Process-Outcomes Link. Cancer, 121, 379-385. [Google Scholar] [CrossRef] [PubMed]
[20] Divrik, R.T., Ahin, A.F., Yildirim, Ü., et al. (2010) Impact of Routine Second Transurethral Resection on the Long-Term Outcome of Patients with Newly Diagnosed pT1 Urothelial Carcino-ma with Respect to Recurrence, Progression Rate, and Disease-Specific Survival: A Prospective Randomised Clinical Trial. European Urology, 58, 185-190. [Google Scholar] [CrossRef] [PubMed]
[21] Steinberg, R.L., Thomas, L.J. and O’Donnell, M.A. (2018) Combination Intravesical Chemotherapy for Non-Muscle- Invasive Bladder Cancer. European Urology Focus, 4, 503-505. [Google Scholar] [CrossRef] [PubMed]
[22] 索杰, 孙羿. 非肌层浸润性膀胱癌整块化手术切除治疗进展[J]. 现代泌尿外科杂志, 2018, 23(6): 471-474.
[23] Babjuk, M., Oosterlinck, W., Sylvester, R., et al. (2008) EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. European Urology, 54, 303-314. [Google Scholar] [CrossRef] [PubMed]
[24] Xia, Y., Kang, T.W., Jung, Y.D., et al. (2019) Sulforaphane Inhibits Nonmuscle Invasive Bladder Cancer Cells Proliferation through Suppression of HIF-1α-Mediated Glycolysis in Hypoxia. Journal of Agricultural and Food Chemistry, 67, 7844-7854. [Google Scholar] [CrossRef] [PubMed]
[25] Shelley, M.D., Court, J.B., Kynaston, H., Wilt, T.J., Coles, B. and Mason, M. (2003) Intravesical Bacillus Calmette-Guerin versus Mitomycin C for Ta and TI Bladder Cancer. Cochrane Database of Systematic Reviews, No. 3, CD003231. [Google Scholar] [CrossRef] 
[26] Sylvester, R.J., Brausi, M.A., Kirkels, W.J., et al. (2010) Long-Term Efficacy Results of EORTC Genito-Urinary Group Randam-ized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. European Urology, 57, 766-773. [Google Scholar] [CrossRef] [PubMed]
[27] Moschini, M., Sharma, I., Delfoglio, P., et al. (2016) Comparing Long-Term Outcomes of Primary and Progressive Carcinoma Invading Bladder Muscle after Radical Cystectomy. BJU International, 17, 604-610. [Google Scholar] [CrossRef] [PubMed]
[28] Wan, J.C.M. (2020) Survival Outcomes of Early versus Deferred Cystec-tomy for High-Grade Non-Muscle-Invasive Bladder Cancer: A Systematic Review. Current Urology, 14, 66-73. [Google Scholar] [CrossRef] [PubMed]

为你推荐